<DOC>
	<DOCNO>NCT00490698</DOCNO>
	<brief_summary>Objectives : Primary : Evaluate clinical outcome base time skeletal event bone-targeted therapy Secondary : 1 . Evaluate clinical outcome base presence calcification site osteolytic metastasis 2 . Measure bone-formation resorption marker baseline bone-targeted therapy . 3 . Assess effect bone-targeted regimen serum cholesterol level</brief_summary>
	<brief_title>Zoledronate With Atorvastatin Renal Cell Carcinoma</brief_title>
	<detailed_description>Kidney cancer often spread ( metastasis ) bone . Zoledronate design protect bone pain break result cancer . Atorvastatin drug lower cholesterol level blood . Combining medication may make zoledronate effective . If find eligible take part study , give zoledronate intravenously ( IV -- needle vein ) fifteen minutes,1 time every 4 week . You take pill , atorvastatin , mouth time day every day study . Every 4 week consider 1 study `` cycle '' . You need return M. D. Anderson check-ups every 8 -12 week . Urine collect routine test . You x-rays , bone scan , and/or CT scan check status disease . You receive least 2 cycle treatment unless intolerable side effect occur disease get bad . You may receive 2 cycle benefit study drug . You follow every 8 week 1 year skeletal event ( symptom relate disease move get bad bone ) . You take study experience skeletal event end 1-year monitoring period . Monitoring may do local doctor M. D. Anderson . No extra test procedure need period . This investigational study . The combination 2 drug give study investigational treatment bone metastasis . Zoledronate approve treatment bone metastasis . Atorvastatin approve FDA lower cholesterol . About 38 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Histologically confirm renal cell carcinoma 2 . Must evidence predominant bone metastases Xrays , bone scan , MRI CT scan . No requirement bidimensionally measurable lesion . 3 . Impending complication ( pathological fracture spinal cord compression ) skeletal metastasis must control surgery radiation therapy . 4 . Patients prior concurrent immunotherapy chemotherapy eligible , exclude drug interact statin ( Cytochrome P450 2C9 Pathway ) . 5 . Patients prior concurrent treatment bisphosphonates statins eligible . 6 . Patients hypercalcemia eligible . 7 . Adequate physiologic reserve evidence : Zubrod performance status &lt; /= 2 ; Transaminase conjugate bilirubin less twice upper limit normal ; Creatinine Clearance &gt; /= 30 ml/min . 8 . Patients must sign informed consent indicate aware investigational nature study . 1 . Patients childbearing potential practicing adequate contraception . 2 . Patients poor dentition recent major dental procedure . 3 . History malignancy nonmelanoma skin cancer carcinomainsitu cervix unless complete remission therapy disease least 5 year . 4 . Overt psychosis mental disability otherwise incompetent give inform consent . 5 . Known hypersensitivity Zometa ( zoledronic acid ) , bisphosphonates , fluvastatin . 6 . Current active dental problem include infection teeth jawbone ( maxilla mandibular ) ; dental fixture trauma , current prior diagnosis osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure . 7 . Recent ( within 6 week ) plan dental jaw surgery ( e.g. , extraction , implant ) 8 . Active liver disease unexplained persistent elevation alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal ( ULN ) 9 . Serum creatine kinase ( CK ) &gt; 3 time ULN 10 . Patients take concurrent agent may increase risk myopathy fibric acid derivative , nicotinic acid , cyclosporine , azole antifungal ( itraconazole , ketoconazole , fluconazole ) , macrolide antibiotic ( erythromycin , clarithromycin , HIV protease inhibitor , nefazodone , delavirdine , cyclosporine , grapefruit juice . 11 . History alcohol abuse condition independently predispose patient myopathy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Kidney Cancer</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Bone-Targeted Therapy</keyword>
	<keyword>Zoledronate</keyword>
	<keyword>Zometa</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Lipitor</keyword>
	<keyword>RCC</keyword>
</DOC>